住院青少年和年轻成人镰状细胞病患者抗凝用于原发和继发性静脉血栓栓塞预防的安全性和有效性:单中心经验
该研究回顾性分析了2015年至2023年住院的镰状细胞病患者,评估抗凝预防静脉血栓栓塞的安全性和有效性。共纳入140名患者的790次住院,其中81.0%接受原发预防,18.4%接受继发预防。发现30例静脉血栓栓塞事件(3.8%),复发/进展率23.3%。脾切除术与静脉血栓栓塞显著相关(OR 4.23,95%CI 1.36-13.15,p=0.0128)。
要点
- 住院镰状细胞病患者静脉血栓栓塞发生率为3.8%,复发/进展率23.3%。
- 脾切除术与静脉血栓栓塞风险显著增加相关(OR 4.23)。
- 尽管使用药物预防,仍有静脉血栓栓塞事件发生,需进一步研究高危患者预防策略。
核心结论
- 尽管使用药物性静脉血栓栓塞预防,仍发生30例静脉血栓栓塞事件,复发/进展率为23.3%。
- 脾切除术与静脉血栓栓塞显著相关(OR 4.23,95%CI 1.36-13.15,p=0.0128)。
- 需要进一步研究以指导血栓风险较高患者的药物预防。
研究设计与样本
- 回顾性审查2015年1月1日至2023年7月11日住院的镰状细胞病患者。
- 共审查140名独特患者的790次住院 encounters。
- 对≥13岁患者提供药物预防。
- 出血和血栓结局按国际血栓与止血学会分类。
- 使用广义logistic混合模型评估静脉血栓栓塞风险。
主要发现
- 中位入院年龄17.2岁(IQR 13.9-19.0)。
- 原发和继发预防性抗凝分别用于81.0%(n=640)和18.4%(n=146)的住院 encounters。
- 在22名个体中识别出30例静脉血栓栓塞事件(3.8%;n=30/790)。
- 发生7例静脉血栓栓塞复发/进展(23.3%)。
- 脾切除术与静脉血栓栓塞显著相关(53.3%;n=16/30 vs 23.3%;n=177/760;OR 4.23,95%CI 1.36-13.15;p=0.0128)。
临床怎么用
- 对于住院镰状细胞病患者,应考虑静脉血栓栓塞风险,尤其是脾切除术后患者。
- 当前药物预防策略可能不足以完全防止静脉血栓栓塞,需个体化评估。
局限性
- 回顾性单中心研究,可能存在选择偏倚。
- 样本量有限,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in sickle cell disease (SCD). The aim of the study was to review the safety and effectiveness of primary and secondary anti-coagulation prophylaxis in hospitalized SCD patient population and to identify potential VTE risk factors. Retrospective review of prescribed anti-coagulants in hospitalized SCD patients from 1 January 2015 to 11 July 2023. Pharmacological prophylaxis was provided to those ≥13 years of age. Bleeding and thrombosis outcomes were classified as per the International Society Thrombosis and Haemostasis. Generalized logistic mixed models with a random intercept for each patient were used to assess VTE risk. Seven hundred and ninety hospital encounters among 140 unique patients were reviewed. Median age at admission: 17.2 years (interquartile range [IQR]: 13.9-19.0). Primary and secondary prophylactic anti-coagulation was prescribed in 81.0% (n = 640) and 18.4% (n = 146) hospital encounters respectively. Thirty VTE events were identified among 22 individuals (3.8%; n = 30/790). Seven VTE recurrences/progression (23.3%) occurred. Surgical splenectomy was significantly associated with VTE (53.3%; n = 16/30) versus those without VTE (23.3%; n = 177/760) (odds ratio 4.23, 95% confidence interval [CI] 1.36-13.15; p = 0.0128). Despite the use of pharmacological VTE prophylaxis, 30 VTE events with a thrombosis recurrence/progression rate of 23.3% occurred. Further studies are needed to guide pharmacological prophylaxis for those at greater thrombosis risk.
引用
- Rodriguez V, Sankar A, Stanek J, et al. Safety and efficacy of anti-coagulation for primary and secondary venous thromboembolism prophylaxis in hospitalized adolescents and young adults with sickle cell disease: An institutional experience. Br J Haematol. 2026. PMID: 41492000. doi:10.1111/bjh.70311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。